Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, Hosseinzadeh-Attar MJ. Jazayeri-Tehrani SA, et al. Among authors: mansouri s. Nutr Metab (Lond). 2019 Jan 28;16:8. doi: 10.1186/s12986-019-0331-1. eCollection 2019. Nutr Metab (Lond). 2019. PMID: 30705687 Free PMC article.
The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
Daneshi-Maskooni M, Keshavarz SA, Mansouri S, Qorbani M, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G. Daneshi-Maskooni M, et al. Among authors: mansouri s. Trials. 2017 Jun 7;18(1):260. doi: 10.1186/s13063-017-1979-3. Trials. 2017. PMID: 28592311 Free PMC article. Clinical Trial.
Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.
Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, Hosseinzadeh-Attar MJ. Jazayeri-Tehrani SA, et al. Among authors: mansouri s. BMJ Open. 2017 Jul 10;7(7):e016914. doi: 10.1136/bmjopen-2017-016914. BMJ Open. 2017. PMID: 28698350 Free PMC article. Clinical Trial.
Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G. Daneshi-Maskooni M, et al. Among authors: mansouri s. Nutr Metab (Lond). 2018 Sep 25;15:63. doi: 10.1186/s12986-018-0297-4. eCollection 2018. Nutr Metab (Lond). 2018. PMID: 30263038 Free PMC article.
Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G. Daneshi-Maskooni M, et al. Among authors: mansouri s. BMC Complement Altern Med. 2019 Mar 12;19(1):59. doi: 10.1186/s12906-019-2465-0. BMC Complement Altern Med. 2019. PMID: 30871514 Free PMC article. Clinical Trial.
Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial.
Naeini F, Namkhah Z, Tutunchi H, Rezayat SM, Mansouri S, Yaseri M, Hosseinzadeh-Attar MJ. Naeini F, et al. Among authors: mansouri s. Eur J Gastroenterol Hepatol. 2022 Mar 1;34(3):345-353. doi: 10.1097/MEG.0000000000002323. Eur J Gastroenterol Hepatol. 2022. PMID: 34860705 Clinical Trial.
Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z, Naeini F, Mahdi Rezayat S, Mehdi Yaseri, Mansouri S, Javad Hosseinzadeh-Attar M. Namkhah Z, et al. Among authors: mansouri s. Int J Clin Pract. 2021 Nov;75(11):e14852. doi: 10.1111/ijcp.14852. Epub 2021 Sep 18. Int J Clin Pract. 2021. PMID: 34516703 Clinical Trial.
402 results